Latest Breaking News On - Cellectis company profile - Page 1 : comparemela.com

Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Stock Performance NASDAQ CLLS opened at $2.71 on Wednesday. The stock has a 50-day simple moving average of $2.77 and a 200 day simple moving […]

Exchange commissionCellectis company profileBaillie gifford coFree reportGet free reportCellectis daily

Cellectis (NASDAQ:CLLS) Now Covered by StockNews com

Investment analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock. Cellectis Stock Performance Shares of Cellectis stock opened at $2.78 on Wednesday. The company has a quick ratio […]

Cellectis company profileExchange commissionBaillie gifford coGet free reportFree reportCellectis daily

Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews com

Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews com
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Principal financial group incExchange commissionCellectis company profileFree reportStock downGet free reportFinancial groupCellectis daily

Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research report report published on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock. Cellectis Stock Up 0.6 % Shares of CLLS opened at $2.51 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio […]

Cellectis company profileFree reportGet free reportCellectis dailyNasdaq cllsInitiated coverageStocknews com

Cellectis (NASDAQ:CLLS) Receives New Coverage from Analysts at StockNews com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Cellectis Price Performance NASDAQ:CLLS opened at $2.51 on Friday. The company’s 50-day moving average price is $2.62 and its 200-day moving average price is $2.65. […]

Cellectis company profileFree reportGet free reportCellectis dailyNasdaq cllsInitiated coverageStocknews com